Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Next Previous
X
Search
Trial Profile

Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilvegostomig (Primary)
  • Indications Adenocarcinoma; Brain metastases; Liver metastases; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ARTEMIDE-01
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 10 Dec 2024 Planned number of patients changed from 192 to 199.
    • 10 Dec 2024 Planned End Date changed from 20 Apr 2026 to 16 Mar 2028.
    • 10 Dec 2024 Planned primary completion date changed from 20 Apr 2026 to 16 Mar 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top